Moleculin to Present at the H.C. Wainwright Global Investment Conference
05/19/2022 - 08:05 AM
HOUSTON , May 19, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. Walter Klemp , President and Chief Executive OfficerH.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website .
A video webcast of the presentation will be available for viewing on-demand beginning Tuesday, May 24, 2022 , at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (www.moleculin.com ). The webcast replay will be archived for 90 days following the event.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
For more information about the Company, please visit www.moleculin.com and connect on Twitter , LinkedIn and Facebook .
Investor Contact:
JTC Team, LLCJenene Thomas MBRX@jtcir.com
https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-hc-wainwright-global-investment-conference-301551061.html
SOURCE Moleculin Biotech, Inc.
MBRX Rankings
#4719 Ranked by Stock Gains
MBRX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
United States
City
Houston
About MBRX
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.
